Celularity (CELU) EBIT (2019 - 2025)

Celularity (CELU) has reported EBIT for 7 consecutive years, with -$22.1 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, EBIT fell 137.69% year-over-year to -$22.1 million in Q4 2025; TTM through Dec 2025 was -$61.3 million, a 59.83% decrease from a year earlier, with the FY2025 full-year figure at -$61.3 million, down 59.83% from the prior year.
• EBIT was -$22.1 million for Q4 2025 at Celularity, down from -$12.9 million in the prior quarter.
• Over five years, EBIT peaked at $17.5 million in Q4 2022 and troughed at -$99.3 million in Q3 2023.
• A 5-year average of -$21.3 million and a median of -$12.2 million in 2024 frame the typical range for EBIT.
• The widest YoY moves for EBIT: up 326.76% in 2021, down 29007.3% in 2021.
• Over 5 years, EBIT stood at -$15.0 million in 2021, then surged by 216.95% to $17.5 million in 2022, then dropped by 23.85% to $13.3 million in 2023, then plunged by 169.7% to -$9.3 million in 2024, then tumbled by 137.69% to -$22.1 million in 2025.
• The last three EBIT figures came in at -$22.1 million (Q4 2025), -$12.9 million (Q3 2025), and -$15.9 million (Q2 2025), per Business Quant data.